Anaesthesia for Duchenne Muscular Dystrophy patients

An evaluation of procedural sedation techniques in Duchenne Muscular Dystrophy patients undergoing stem cell therapy

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2017/08/009462

Enrollment

Registered

2017-08-23

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- DUCHENNE MUSCULAR DYSTROPHY PATIENTS ASA 1 AND 2 Health Condition 2: G132- Systemic atrophy primarily affecting the central nervous system in myxedema

Interventions

Control Intervention1: Nil: Nil

Eligibility

Inclusion criteria

Inclusion criteria: Patients of DMD undergoing procedural sedation techniques Age more than 5years

Exclusion criteria

Exclusion criteria: 1) unwilling for consent 2) patient not requiring any sort of sedation 3) patient needing general anaesthesia and assisted ventilation with or without tracheal intubation due to any reason

Design outcomes

Primary

Measure	Time frame
Dexmedetomidine and ketamine together will have a better heamodynamic profile, sedation score,as compared to given aloneTimepoint: Every 5 minutes heamodynamic profile, sedation score were checked till the completion of procedure	—

Secondary

Measure	Time frame
Adverse effects of dexmedetomidine and ketamineTimepoint: At 5 minutes interval during the procedure we should study the effects of dexmedetomidine and ketamine	—

Countries

India

Contacts

Public ContactMadhuri Jagtap

Lokamanya tilak municipal medical college nd hospitals

dr_hemangi@hotmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026